Five seconds from trigger to detonation, and almost no trace left behind. A defence mechanism nobody knew existed, in an animal that regenerates from fragments.
The trial was stopped early for efficacy — and lands in a subtype that had almost nothing five years ago and now has three approved drugs competing.
Continuous glucose monitoring transformed diabetes care. Ketones — the warning sign for a life-threatening emergency — still required a finger stick. Libre Duo puts both in one sensor.
T-cell engagers were built to kill cancer cells. Pointing them at a patient’s own misbehaving immune cells is the same weapon aimed inward.
A $2.3 billion campus producing small molecules, biologics and ADCs — announced ten days after 100% tariffs on some foreign-made treatments took effect.
Triple-negative breast tumours recruit immune cells to release a nerve growth signal, then grow their own nerve supply. An approved drug blocks that signal.
It was not immune weakness that woke the sleeping viruses. It was inflammation — and one obscure virus family tracked with long COVID.
Molecular glues were found by accident — lenalidomide sold for years before anyone knew how it worked. This turns the accident into a search.
Not an acquisition — an incubator place. Lilly gets a window onto an RNA platform without buying it, and Rznomics gets lab space and US infrastructure it would take years to build.
A rare hybrid T cell made up 4% of T cells in 70-somethings, 9.6% in centenarians and 17.6% in people past 110. The immune system may still be adapting at an age when everything else is declining.
Antibiotics reshaping gut bacteria is expected. Benzodiazepines doing it to a comparable degree is not — and the effects were still detectable years after people stopped.
KRAS is mutated in 90% of pancreatic cancers. This drug addresses the 1–2% with the one subtype chemistry has learned to hit.